Prioritizing new malaria vaccine candidates for further development
Prioritizing new malaria vaccine candidates for further development Prioritizing new malaria vaccine candidates for further development
Updating the Malaria Vaccine Technology Roadmap Expanded Strategic Goals – Part 2 (draft) Strategic Goals after first public consultation in Oct 2012 In the 2025 to 2050 timeframe, license safe vaccines targeting malaria species with significant global disease burden and encompassing the following two objectives, for use by the international public health community: 1 2) Malaria vaccines that inhibit transmission 4 of the parasite and thereby substantially reduce the incidence of human malaria infection to achieve elimination in multiple settings, in conjunction with other malaria control tools. The vaccines should be suitable for administration to people of all ages in mass campaigns. 5 Additional new strategic goal • Inhibit transmission* • Reduce incidence of malaria infections • Achieve elimination in multiple settings • All ages • Mass campaigns *Not restricted to any one life-cycle stage or vaccine approach http://www.who.int/vaccine_research/diseases/malaria/ Roadmap_update_for_second_public_consultation.pdf 14
Strategic goals, outcomes, and vaccine targets Goal/impact Control & elimination Saving lives & preventing disease 15
- Page 1 and 2: Prioritizing New Malaria Vaccine Ca
- Page 3 and 4: Why prioritize • No need to prior
- Page 5 and 6: Global malaria vaccine pipeline Pha
- Page 7 and 8: What to prioritize • Strategic go
- Page 9 and 10: The Malaria Vaccine Technology Road
- Page 11 and 12: 1 2 Reasons to update the Roadmap
- Page 13: Updating the Malaria Vaccine Techno
- Page 17 and 18: Strategic goals, outcomes, and vacc
- Page 19 and 20: Thoughts on how vaccine candidates
- Page 21 and 22: Cost Low High A commercial-sector m
- Page 23 and 24: Cost Low High A commercial-sector m
- Page 25 and 26: Sources and management of uncertain
- Page 27 and 28: Prioritizing through defining/manag
- Page 29 and 30: Summary • There is an ongoing nee
Updating the Malaria Vaccine Technology Roadmap<br />
Expanded Strategic Goals – Part 2 (draft)<br />
Strategic Goals after first<br />
public consultation in Oct 2012<br />
In the 2025 to 2050 timeframe, license<br />
safe <strong>vaccine</strong>s targeting <strong>malaria</strong><br />
species with significant global disease<br />
burden and encompassing the<br />
following two objectives, <strong>for</strong> use by the<br />
international public health community: 1<br />
2) Malaria <strong>vaccine</strong>s that inhibit<br />
transmission 4 of the parasite and<br />
thereby substantially reduce the<br />
incidence of human <strong>malaria</strong> infection to<br />
achieve elimination in multiple settings,<br />
in conjunction with other <strong>malaria</strong> control<br />
tools. The <strong>vaccine</strong>s should be suitable<br />
<strong>for</strong> administration to people of all ages<br />
in mass campaigns. 5<br />
Additional <strong>new</strong> strategic goal<br />
• Inhibit transmission*<br />
• Reduce incidence of<br />
<strong>malaria</strong> infections<br />
• Achieve elimination in<br />
multiple settings<br />
• All ages<br />
• Mass campaigns<br />
*Not restricted to any one life-cycle<br />
stage or <strong>vaccine</strong> approach<br />
http://www.who.int/<strong>vaccine</strong>_research/diseases/<strong>malaria</strong>/<br />
Roadmap_update_<strong>for</strong>_second_public_consultation.pdf<br />
14
Change language